glp 1 1 month results GLP-1 journey: 25 pounds down in just 3 months! 🙂‍↔️ This transformation started in July, and the speak for themselves! At EC, we're all about true support – not just handing Semaglutide Alpharetta - Thrive Medical

Heat shock transcription factor 2 reduces the secretion of IL-1 by inhibiting NLRP3 inflammasome activation in ulcerative colitis

Common early experiences include: Reduced appetite : Many people notice decreased hunger and earlier satiety during meals within days of the first injection or dose Mild gastrointestinal symptoms : Nausea (affecting 2040% of patients), occasional vomiting, or changes in bowel habits are usually mild and transient Injection site reactions : Minor redness, itching, or discomfort at injection sites is common but typically resolves quickly Fatigue : Some individuals report feeling more tired initially as their body adjusts to reduced calorie intake By weeks 24 , appetite suppression typically becomes more pronounced, and patients often find it easier to adhere to portion control and dietary modifications

Clinical data suggests semaglutide users report nausea in approximately 25-30% of cases, whereas tirzepatide shows nausea in 30-40% of users, likely due to dual-pathway activation creating stronger initial gastrointestinal effects

Therefore, the drug may overcome a challenge of diet and exercise, where the brain compensates for weight loss by lowering metabolic rate, making it difficult to maintain lower weight long-term

[DOI] [PubMed] [Google Scholar] [12].Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, Pipeleers D, Ling Z, Drucker DJ, GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress, Cell Metab, 4 (2006) 391406

Muscle loss is a significant concern, given tirzepatide's better lean mass preservation data